QUEBEC CITY, Aug. 15, 2016 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) announced today that OptoWire's performance was highlighted in the Circulation Journal, the Official Journal of the Japanese Circulation Society.
The article, written jointly by Dr. Nico HJ Pijls and Dr. Bernard de Bruyne is called "Fractional Flow Reserve, Coronary Pressure Wires, and Drift". The article highlights the fact that traditional guidewires showed an inevitable drift of the measure, despite major efforts to minimize it. It is said that the occurrence of drift is the most annoying problem that can occur during a procedure in a patient because it is often unnoticed before the wire is pulled back to the guiding catheter at the end of the procedure, and if it is present, it may invalidate the measurement. In the article, it is mentioned that in their laboratories, they used approximately 100 OptoWire in the past year and they have not observed any drift in any of the OptoWire up to now.
Opsens commercialized the OptoWire, an optical guidewire to measure the Fractional Flow Reserve ("FFR"). This measurement is used to optimize the diagnosis and guide the treatment of patients with coronary heart disease.
"Opsens is honored to see a significant strength of its patented optical pressure guidewire such as the accuracy of the measurement being recognized by the founding fathers of FFR. In the future, Opsens aims to contribute to FFR growth by providing high-performance products to the cardiology community "said Louis Laflamme, President and CEO of Opsens.
Opsens aims to become a key player in the guidewire FFR market with the OptoWire, a nitinol-based optical guidewire. The OptoWire provides intra-coronary blood pressure measurements with unique, patented optical pressure guidewire technologies. It is immune to adverse effects related to blood contact, and allows easy and reliable connectivity that leads to reliable FFR measurements in extended conditions of usage. The OptoWire is also designed to provide cardiologists with a guidewire that provides optimal performance to navigate coronary arteries and cross blockages with ease and safety. Based on industry sources, the FFR market represented more than US$300 million in sales in 2014 and is expected to reach US$1 billion in the medium-term.
About Opsens Inc. (www.opsens.com or www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE OPSENS INC.
For further information: Thierry Dumas, CPA, CA, Chief Financial Officer, 418.781.0333; Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333